Authorized in France since November 2006. Indicated for 14-year-old adolescents, with a catch-up up to 23 years for those who have not yet had sex, 800,000 young French women have already benefited from it. The vaccine consists of three injections. Of the 800,000 young women who received it, 400,000 received a single dose, 200,000 two doses, and 200,000 all three doses. The majority of prescriptions concern “catch-ups between 15 and 23 years”. Only 14% of those vaccinated are 14-year-old girls.
Since November 2006, 700 notifications have been registered, mainly concerning mild and transient adverse effects.
According to Afssaps, “the surveillance data do not call into question the benefit risk ratio of the vaccine”.
